Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RT-114 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity | COMBINATION_PRODUCT | RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity. |
| PG-102 | DRUG | PG-102 is a drug for the treatment of obesity. |
| Placebo | OTHER | The placebo is the RaniPill with saline instead of a drug. |
Top 20 of 36 competitors
RT-114 is an investigational oral capsule being developed for the treatment of obesity. It combines the RaniPill capsule with PG-102, a GLP-1/GLP-2 receptor agonist. Rani Therapeutics Holdings, Inc. is developing RT-114, which is currently in Phase 1 clinical development.
RT-114 is being developed for the treatment of obesity. It is designed to deliver PG-102, a GLP-1/GLP-2 receptor agonist, orally using the RaniPill capsule. The program is in Phase 1 testing and has not been approved for any indication.
RT-114 targets the GLP-1 and GLP-2 receptors. PG-102, the active agent delivered by the RaniPill capsule, acts as a GLP-1/GLP-2 receptor agonist. This dual receptor activity is the basis for its development in obesity.
RT-114 is being developed by Rani Therapeutics Holdings, Inc., which trades under the ticker RANI. The company is advancing RT-114, an oral RaniPill capsule formulation of PG-102, for obesity.
RT-114 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial is registered, and it is not yet recruiting participants.
RT-114 is being studied in one Phase 1 trial, NCT06891287, titled An Early Phase Study of RT-114. The trial targets enrollment of 60 participants with obesity, is uncontrolled, and its status is not yet recruiting.